Glucagon use by US adults with type 1 and type 2 diabetes

被引：19

作者：

Kahn, Peter A. ^{[1
]}

Liu, Shuling ^{[2
]}

McCoy, Rozalina ^{[3
,4
,5
]}

Gabbay, Robert A. ^{[6
]}

Lipska, Kasia ^{[2
,7
]}

机构：

[1] Yale Sch Med, Dept Internal Med, New Haven, CT 06520 USA

[2] Yale New Haven Med Ctr, Ctr Outcomes Res & Evaluat, 20 York St, New Haven, CT 06504 USA

[3] Mayo Clin, Dept Med, Div Community Internal Med, Rochester, MN USA

[4] Mayo Clin, Dept Hlth Sci Res, Div Hlth Care Policy & Res, Rochester, MN USA

[5] OptumLabs, Cambridge, MA USA

[6] Harvard Med Sch, Joslin Diabet Ctr, Boston, MA 02115 USA

[7] Yale Sch Med, Sect Endocrinol, Dept Internal Med, POB 208020, New Haven, CT 06520 USA

来源：

JOURNAL OF DIABETES AND ITS COMPLICATIONS | 2021年 / 35卷 / 05期

关键词：

Hypoglycemia; Glucagon; Type; 1; diabetes; 2; Adverse drug events;

D O I：

10.1016/j.jdiacomp.2021.107882

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The American Diabetes Association recommends that all patients at risk for hypoglycemia be prescribed glucagon. Despite this recommendation, there is evidence that prescription rates are lower than expected for patients with type 1 and type 2 diabetes. This study investigated prescription patterns for glucagon among de-identified administrative claims from OptumLabs (R) Data Warehouse for prescriptions between January 1, 2014 and December 31, 2014 among pharmacologically treated type 1 and 2 diabetes patients. We find that glucagon was rarely filled by patients with type 1 and type 2 diabetes, including fewer than 5% of patients with prior hypoglycemia requiring emergency healthcare utilization. Among patients with type 1 diabetes, glucagon fills were unpredictable and not targeted to highest risk patients. (c) 2021 Published by Elsevier Inc.

引用

页数：4

共 6 条

[1] Glycemic Targets: Standards of Medical Care in Diabetes-2019 [J].

Cefalu, William T. ;

Berg, Erika Gebel ;

Saraco, Mindy ;

Petersen, Matthew P. ;

Uelmen, Sacha ;

Robinson, Shamera .

DIABETES CARE, 2019, 42 :S61-S70

[2]

Centers for Disease Control and Prevention, 2006, NUMB EM DEP VIS 1000

[3] GLUCAGON PRESCRIPTION PATTERNS IN PATIENTS WITH EITHER TYPE 1 OR 2 DIABETES WITH NEWLY PRESCRIBED INSULIN [J].

Mitchell, Beth D. ;

He, Xuanyao ;

Sturdy, Ian M. ;

Cagle, Andrew P. ;

Settles, Julie A. .

ENDOCRINE PRACTICE, 2016, 22 (02) :123-135

[4]

OptumLabs, 2020, OPTUMLABS OPTUMLABS

[5]

Quilliam BJ, 2011, AM J MANAG CARE, V17, P673

[6] Intranasal Glucagon for Treatment of Insulin-Induced Hypoglycemia in Adults With Type 1 Diabetes: A Randomized Crossover Noninferiority Study [J].

Rickels, Michael R. ;

Ruedy, Katrina J. ;

Foster, Nicole C. ;

Piche, Claude A. ;

Dulude, Helene ;

Sherr, Jennifer L. ;

Tamborlane, William V. ;

Bethin, Kathleen E. ;

DiMeglio, Linda A. ;

Wadwa, R. Paul ;

Ahmann, Andrew J. ;

Haller, Michael J. ;

Nathan, Brandon M. ;

Marcovina, Santica M. ;

Rampakakis, Emmanouil ;

Meng, Linyan ;

Beck, Roy W. .

DIABETES CARE, 2016, 39 (02) :264-270

← 1 →